Metraipolis › archive › dc_61e09815c052

Clinical features and HLA typing of immune checkpoint inhibitor-associated myasthenia gravis, myocarditis and myositis — Europe PMC PMID:41357573

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41357573
DOI
10.3389/fonc.2025.1646231
License (as archived)
solo-consultazione
Archived
2026-11-08T08:50:04.408Z
SHA-256 of the archived text
2b4548a628409e780cd7d684ca1b311e4e233611d954703cd0e9325b2c6d64d9
Stable URL of this page
https://metraipolis.com/documento/dc_61e09815c052

How to cite

Clinical features and HLA typing of immune checkpoint inhibitor-associated myasthenia gravis, myocarditis and myositis — Europe PMC PMID:41357573 — Europe PMC (en), https://europepmc.org/article/MED/41357573 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_61e09815c052 (Metraipolis archive dc_61e09815c052, sha256 2b4548a628409e780cd7d684ca1b311e4e233611d954703cd0e9325b2c6d64d9)
BibTeX
@misc{dc61e09815c052,
  title = {Clinical features and HLA typing of immune checkpoint inhibitor-associated myasthenia gravis, myocarditis and myositis — Europe PMC PMID:41357573},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41357573},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_61e09815c052; sha256 2b4548a628409e780cd7d684ca1b311e4e233611d954703cd0e9325b2c6d64d9},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41357573. Agents can read the archived copy with the MCP tool read_document.